EPKINLY Trial Results Prompt Price Target Cut for Genmab (GMAB)
Genmab A/S (NASDAQ:GMAB) ranks among the best high growth European stocks to buy. On January 20, H.C.
Genmab A/S (GMAB)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bayforest Capital Theodoros Tsagaris | 5,208 | $160,406 | -56% | 0.12% |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,098,550 | $33,835,340 | 0.03% | |
| 2. | 827,217 | $25,478,283 | 0.37% | |
| 3. | 364,756 | $11,234,485 | 0.14% | |
| 4. | 249,310 | $7,678,748 | 0.28% | |
| 5. | 233,852 | $7,202,642 | 0.01% |
News See All
10 High Growth European Stocks To Buy
European equities began the last week of January in a sour mood, with investors concerned on January 26 about rising geopolitical tensions in anticipation of a Federal Reserve policy meeting and a flood...
Genmab (GMAB)’s Future Potential Underappreciated by Market
Orbis Investment Management released its Q4 2025 investor letter for “Orbis SICAV International Equity Fund”.
Genmab A/S (GMAB) Shares Gain Analyst Support as Deutsche Bank Sees Oncology Upside
TheFly reported on January 8 that Deutsche Bank raised its price target for GMAB to DKK 2,400 from DKK 2,000 and reiterated a Buy rating, reflecting analysts’ optimism about the company’s late-stage...
Top 10 Oncology Stocks to Buy Now
The oncology market in the United States was estimated at $81.34 billion in 2025 and is expected to reach $211.78 billion by 2034 with a compound annual growth rate of 11.75%.
Genmab A/S (GMAB): A Bull Case Theory
We came across a bullish thesis on Genmab A/S on Gabriel Koh’s Substack. In this article, we will summarize the bulls’ thesis on GMAB. Genmab A/S's share was trading at $33.87 as of January 13th.
Here’s Why Genmab A/S (GMAB) Rose in Q3
Chautauqua Capital Management, a division of Baird Asset Management, is a boutique investment firm that released its third-quarter 2025 investor letter for the “Baird Chautauqua International and Global...
Genmab A/S (NASDAQ:GMAB) Q3 2025 Earnings Call Transcript
Operator: Hello, and welcome to the Genmab First Half 2025 Financial Results Conference Call. As a reminder, this conference call is being recorded.
H.C. Wainwright Maintains a Buy Rating on Genmab A/S (GMAB)
Genmab A/S (NASDAQ:GMAB) is one of the most profitable biotech stocks to buy. H.C.
9 Most Profitable Biotech Stocks to Buy
On October 6, StemPoint Capital CIO Michelle Ross appeared on CNBC’s ‘Closing Bell’ to talk about the biotech space.
Hedge Fund Resource Center Billionaire Hedge Funds
